Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions.

drug protocol number
19-2017
drug sponsor
MEDIS Laboratories
drug study
Tacrolimus/ Prograf
drug trial site
Saudi Ajal
drug status
Ongoing
drug phase